Lazertinib has been established as an effective treatment for EGFR‐mutant NSCLC, either as monotherapy or in combination with other agents, in both first‐ and subsequent‐line settings, as demonstrated in the LASER301, MARIPOSA, and MARIPOSA‐2 trials [6, 7, 8]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.